TRACON Pharmaceuticals (TCON) Announces Quarterly Earnings Results
TRACON Pharmaceuticals (NASDAQ:TCON) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03), Fidelity Earnings reports.
NASDAQ TCON opened at $0.68 on Thursday. The company has a market capitalization of $20.03 million, a price-to-earnings ratio of -0.53 and a beta of 2.78. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.25. TRACON Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $3.20.
Several research firms have commented on TCON. Zacks Investment Research cut TRACON Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 8th. Needham & Company LLC restated a “buy” rating and issued a $7.00 target price on shares of TRACON Pharmaceuticals in a research note on Friday, March 1st. Finally, BTIG Research cut TRACON Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, April 12th.
COPYRIGHT VIOLATION WARNING: This article was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2019/05/16/tracon-pharmaceuticals-tcon-announces-quarterly-earnings-results.html.
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.
See Also: Penny Stocks
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.